Craxì A, Valenza M, Fabiano C, Magrin S, Fiorentino G, Diquattro O, Pagliaro L
Instituto Medicina Generale, University of Palermo, Italy.
J Hepatol. 1994 Nov;21(5):730-4. doi: 10.1016/s0168-8278(94)80231-9.
This study evaluated the performance of third-generation anti-HCV assays in blood donors who were positive by second-generation anti-HCV, and assessed any possible relationship between antibody patterns, HCV replication and liver damage. Fifty-two second-generation enzyme immunoassay-positive asymptomatic Italian blood donors were retested for anti-HCV by third-generation enzyme immunoassay and recombinant immunoblot assay (Ortho third-generation enzyme immunoassay, third-generation recombinant immunoblot assay), utilising recombinant C33c and NS5 and synthetic peptide C100 and C22 antigens, and for HCV-RNA by "nested" polymerase chain reaction with 5' region primers. Alanine aminotransferases were tested monthly for 6 months. Two out of 52 second-generation enzyme immunoassay-positive donors were third-generation enzyme immunoassay, third-generation recombinant immunoblot assay and HCV-RNA negative. Among 50 third-generation enzyme immunoassay-positive cases, two had a third-generation enzyme immunoassay optical density < or = 1: one was third-generation recombinant immunoblot assay and HCV-RNA negative, and the other was third-generation recombinant immunoblot assay "indeterminate" and HCV-RNA-positive. The remaining 48 cases had third-generation enzyme immunoassay optical density > 1: six were third-generation recombinant immunoblot assay negative (one HCV-RNA+ve), eight "indeterminate" (two HCV-RNA+ve) and 34 positive (22 HCV-RNA+ve). All "indeterminate" subjects reacted only to C22. HCV-RNA was positive in 22/34 cases with positive third-generation recombinant immunoblot assay (two or more Ags), 3/9 "indeterminate" and 1/11 negative. Alanine amino-transferases were abnormal in 13 cases with positive third-generation recombinant immunoblot assay, one was "indeterminate" and three were negative.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究评估了第三代抗丙型肝炎病毒(HCV)检测方法在第二代抗HCV检测呈阳性的献血者中的表现,并评估了抗体模式、HCV复制与肝损伤之间的任何可能关系。对52名第二代酶免疫检测呈阳性的无症状意大利献血者,采用第三代酶免疫检测和重组免疫印迹检测(Ortho第三代酶免疫检测、第三代重组免疫印迹检测),利用重组C33c和NS5以及合成肽C100和C22抗原进行抗HCV复测,并通过使用5'区域引物的“巢式”聚合酶链反应检测HCV-RNA。连续6个月每月检测丙氨酸转氨酶。52名第二代酶免疫检测呈阳性的献血者中,有2名在第三代酶免疫检测、第三代重组免疫印迹检测及HCV-RNA检测中均为阴性。在50名第三代酶免疫检测呈阳性的病例中,2例第三代酶免疫检测光密度≤1:1例第三代重组免疫印迹检测及HCV-RNA阴性,另1例第三代重组免疫印迹检测“不确定”且HCV-RNA阳性。其余48例第三代酶免疫检测光密度>1:6例第三代重组免疫印迹检测阴性(1例HCV-RNA阳性),8例“不确定”(2例HCV-RNA阳性),34例阳性(22例HCV-RNA阳性)。所有“不确定”的受试者仅对C22有反应。第三代重组免疫印迹检测呈阳性(两种或更多抗原)的34例病例中,22例HCV-RNA阳性,9例“不确定”中有3例,11例阴性中有1例。第三代重组免疫印迹检测呈阳性的13例病例中丙氨酸转氨酶异常,1例“不确定”,3例阴性。(摘要截短于250字)